While medicinal inorganic chemistry has been practised for over 5000 years, it was not until
the late 1800s when Alfred Werner published his ground-breaking research on coordination …

Cancer is rapidly becoming the top killer in the world. Most of the FDA approved anticancer
drugs are organic molecules, while metallodrugs are very scarce. The advent of the first …

Anticancer metallodrugs based on ruthenium and osmium are among the most investigated
and advanced non-platinum metallodrugs. Inorganic drug discovery with these agents has …

Half-sandwich Ru (II) complexes containing nitro-substituted furoylthiourea ligands, bearing
the general formula [(η 6-p-cymene) RuCl2 (L)](1–6) and [(η 6-p-cymene) RuCl …

Ruthenium complexes with bioactive ligands are becoming promising substitutes for
platinum complexes due to their precise action against various cancers. In the present study …

As anticipated in the title, this contribution is basically divided into two, strictly connected,
parts. The first is a personal overview of the ruthenium drug candidate NAMI‐A, almost 30 …

Abstract Ruthenium (II)-arene RAPTA-type compounds have been extensively explored for
their medicinal properties. Herein a comprehensive review of this class of compounds is …

In this review we summarize our work on development of Ru complexes with potential
antitumor activity, which was performed over the last few years. In order to establish the …

A panel of six new structurally related organometallic arene Ru (II) complexes of general
composition [(η6-benzene) Ru (L) Cl](1–3) and [(η6-p-cymene) Ru (L) Cl](4–6)(L …

Platinum complexes are widely used anticancer drugs. New generations of metal
chemotherapeutics offer the prospect of combating platinum resistance and expanding the …